{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:04:13Z","timestamp":1785261853091,"version":"3.55.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008061","name":"Mutua Madrile\u00f1a Foundation","doi-asserted-by":"publisher","award":["AP18051-2022"],"award-info":[{"award-number":["AP18051-2022"]}],"id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI22\/01700"],"award-info":[{"award-number":["PI22\/01700"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI23\/00722"],"award-info":[{"award-number":["PI23\/00722"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Patolog\u00eda"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.patol.2026.100859","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:22:41Z","timestamp":1772097761000},"page":"100859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["SEAP-GETNE consensus on prognostic and predictive molecular biomarkers in thyroid cancer"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2298-4683","authenticated-orcid":false,"given":"Ignacio","family":"Ruz-Caracuel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Alonso-Gordoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Rodrigo-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Jimenez-Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hern\u00e1n Dario","family":"Quiceno-Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Lorenzo-Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Rosa","family":"Bella-Cueto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Cameselle-Teijeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Capdevila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.patol.2026.100859_bib0485","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.patol.2026.100859_bib0490","unstructured":"Las_cifras_del_Cancer_en_Espana_2023.pdf [Internet]. Available from: https:\/\/seom.org\/images\/Las_cifras_del_Cancer_en_Espana_2023.pdf Cited 13.1.24."},{"key":"10.1016\/j.patol.2026.100859_bib0495","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1072-7515(03)00332-6","article-title":"Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma","volume":"197","author":"Shoup","year":"2003","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.patol.2026.100859_bib0500","first-page":"866","article-title":"Long-term outcome of differentiated thyroid cancer patients-fifty years of Croatian thyroid disease referral centre experience","volume":"12","author":"Juki\u0107","year":"2022","journal-title":"Diagn Basel Switz"},{"key":"10.1016\/j.patol.2026.100859_bib0505","first-page":"2902","article-title":"SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023)","volume":"26","author":"Alonso-Gordoa","year":"2024","journal-title":"Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex"},{"key":"10.1016\/j.patol.2026.100859_bib0510","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","article-title":"Overview of the 2022 WHO classification of thyroid neoplasms","volume":"33","author":"Baloch","year":"2022","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.patol.2026.100859_bib0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01662011","article-title":"Beitr\u00e4ge zur kenntniss des secretionsvorgangs in der schilddr\u00fcse","volume":"56","author":"H\u00fcrthle","year":"1894","journal-title":"Arch F\u00fcr Gesamte Physiol Menschen Tiere"},{"key":"10.1016\/j.patol.2026.100859_bib0520","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12022-021-09665-2","article-title":"Molecular pathology of poorly differentiated and anaplastic thyroid cancer: what do pathologists need to know?","volume":"32","author":"Volante","year":"2021","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.patol.2026.100859_bib0525","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1089\/thy.2020.0086","article-title":"Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases","volume":"30","author":"Xu","year":"2020","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.patol.2026.100859_bib0530","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.21.01329","article-title":"International medullary thyroid carcinoma grading system: a validated grading system for medullary thyroid carcinoma","volume":"40","author":"Xu","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.patol.2026.100859_bib0535","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s12022-024-09820-5","article-title":"Primary secretory carcinoma of the thyroid gland with ETV6::NTRK3 gene fusion","volume":"35","author":"Whaley","year":"2024","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.patol.2026.100859_bib0540","first-page":"1168","article-title":"Cribriform-morular variant of thyroid carcinoma: a neoplasm with distinctive phenotype associated with the activation of the WNT\/\u03b2-catenin pathway","volume":"31","author":"Cameselle-Teijeiro","year":"2018","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"10.1016\/j.patol.2026.100859_bib0545","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00428-020-02853-1","article-title":"Malignant teratoid tumor of the thyroid gland: an aggressive primitive multiphenotypic malignancy showing organotypical elements and frequent DICER1 alterations-is the term \u2018thyroblastoma\u2019 more appropriate?","volume":"477","author":"Agaimy","year":"2020","journal-title":"Virchows Arch Int J Pathol"},{"key":"10.1016\/j.patol.2026.100859_bib0550","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1089\/thy.2022.0060","article-title":"Primary thyroid neoplasm with fetal morphology associated with DICER1 mutations: expanding the diagnostic profile of thyroblastoma","volume":"32","author":"Guilmette","year":"2022","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.patol.2026.100859_bib0555","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","article-title":"BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence","volume":"32","author":"Xing","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.patol.2026.100859_bib0560","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jama.2013.3620","article-title":"Molecular testing in thyroid cancer: BRAF mutation status and mortality","volume":"309","author":"Cappola","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.patol.2026.100859_bib0565","first-page":"779","article-title":"Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET\/PTC rearrangements","volume":"20","author":"Sheu","year":"2007","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"10.1016\/j.patol.2026.100859_bib0570","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1089\/thy.2017.0059","article-title":"Molecular testing for oncogenic gene alterations in pediatric thyroid lesions","volume":"28","author":"Mostoufi-Moab","year":"2018","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.patol.2026.100859_bib0575","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1007\/s12325-020-01391-1","article-title":"Papillary thyroid cancer-aggressive variants and impact on management: a narrative review","volume":"37","author":"Coca-Pelaz","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.patol.2026.100859_bib0580","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.isci.2019.09.030","article-title":"Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing","volume":"20","author":"Ciampi","year":"2019","journal-title":"iScience"},{"key":"10.1016\/j.patol.2026.100859_bib0585","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s12022-021-09664-3","article-title":"Genomics and epigenomics of medullary thyroid carcinoma: from sporadic disease to familial manifestations","volume":"32","author":"Barletta","year":"2021","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.patol.2026.100859_bib0590","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1210\/jc.2007-1714","article-title":"Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study","volume":"93","author":"Elisei","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.patol.2026.100859_bib0595","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2023.0482","article-title":"Tumor grade and molecular characteristics associated with survival in sporadic medullary thyroid carcinoma","volume":"34","author":"Censi","year":"2024","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.patol.2026.100859_bib0600","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/thy.2023.0279","article-title":"Association of the genomic profile of medullary thyroid carcinoma with tumor characteristics and clinical outcomes in an international multicenter study","volume":"34","author":"Xu","year":"2024","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.patol.2026.100859_bib0605","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005467","article-title":"Identification of driving ALK fusion genes and genomic landscape of medullary thyroid cancer","volume":"11","author":"Ji","year":"2015","journal-title":"PLoS Genet"},{"key":"10.1016\/j.patol.2026.100859_bib0610","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/PAS.0000000000002153","article-title":"Divergent lineage markers in anaplastic thyroid carcinoma","volume":"48","author":"Mneimneh","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.patol.2026.100859_bib0615","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/annonc\/mdy123","article-title":"Early evolutionary divergence between papillary and anaplastic thyroid cancers","volume":"29","author":"Capdevila","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.patol.2026.100859_bib0620","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12022-016-9445-4","article-title":"Genomic landscape of poorly differentiated and anaplastic thyroid carcinoma","volume":"27","author":"Xu","year":"2016","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.patol.2026.100859_bib0625","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/his.14144","article-title":"Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma","volume":"77","author":"Chen","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.patol.2026.100859_bib0630","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/hed.25634","article-title":"Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling","volume":"41","author":"Khan","year":"2019","journal-title":"Head Neck"},{"key":"10.1016\/j.patol.2026.100859_bib0635","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.patol.2026.100859_bib0640","first-page":"2029","article-title":"Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing","volume":"35","author":"Sykorova","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.patol.2026.100859_bib0645","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11912-021-01019-9","article-title":"Anaplastic thyroid carcinoma: current issues in genomics and therapeutics","volume":"23","author":"Abe","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.patol.2026.100859_bib0650","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/his.13942","article-title":"Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing","volume":"75","author":"Duan","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.patol.2026.100859_bib0655","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/thy.2020.0944","article-title":"2021 American Thyroid Association Guidelines for management of patients with anaplastic thyroid cancer","volume":"31","author":"Bible","year":"2021","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.patol.2026.100859_bib0660","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3892\/ol.2021.12814","article-title":"PD-L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: a retrospective study","volume":"22","author":"Cameselle-Garc\u00eda","year":"2021","journal-title":"Oncol Lett"},{"key":"10.1016\/j.patol.2026.100859_bib0665","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.19.02727","article-title":"PD-1 blockade in anaplastic thyroid carcinoma","volume":"38","author":"Capdevila","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.patol.2026.100859_bib0670","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12022-020-09661-y","article-title":"Inherited follicular epithelial-derived thyroid carcinomas: from molecular biology to histological correlates","volume":"32","author":"Cameselle-Teijeiro","year":"2021","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.patol.2026.100859_bib0675","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12022-024-09836-x","article-title":"Consensus statement: recommendations on actionable biomarker testing for thyroid cancer management","volume":"35","author":"Mete","year":"2024","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.patol.2026.100859_bib0680","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.829103","article-title":"Susceptibility genes and chromosomal regions associated with non-syndromic familial non-medullary thyroid carcinoma: some pathogenetic and diagnostic keys","volume":"13","author":"S\u00e1nchez-Ares","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.patol.2026.100859_bib0685","doi-asserted-by":"crossref","first-page":"E1562","DOI":"10.1210\/jc.2013-2383","article-title":"Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease","volume":"98","author":"Landa","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.patol.2026.100859_bib0690","doi-asserted-by":"crossref","first-page":"E754","DOI":"10.1210\/jc.2013-3734","article-title":"TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas","volume":"99","author":"Melo","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.patol.2026.100859_bib0695","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1530\/ERC-18-0050","article-title":"TERT aberrancies: a screening tool for malignancy in follicular thyroid tumours","volume":"25","author":"Paulsson","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.patol.2026.100859_bib0700","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1089\/thy.2018.0695","article-title":"TERT mRNA expression as a novel prognostic marker in papillary thyroid carcinomas","volume":"29","author":"Tanaka","year":"2019","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.patol.2026.100859_bib0705","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/his.14550","article-title":"Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases","volume":"80","author":"Xu","year":"2022","journal-title":"Histopathology"},{"key":"10.1016\/j.patol.2026.100859_bib0710","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12020-024-03990-2","article-title":"Minor role of TP53 and TERT promoter mutations in medullary thyroid carcinoma: report of new cases and revision of the literature","volume":"87","author":"Casalini","year":"2025","journal-title":"Endocrine"},{"key":"10.1016\/j.patol.2026.100859_bib0715","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.5858\/arpa.2019-0009-SA","article-title":"Preanalytics and precision pathology: pathology practices to ensure molecular integrity of cancer patient biospecimens for precision medicine","volume":"143","author":"Compton","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.patol.2026.100859_bib0720","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.5858\/arpa.2018-0172-OA","article-title":"The biospecimen preanalytical variables program: a multiassay comparison of effects of delay to fixation and fixation duration on nucleic acid quality","volume":"143","author":"Carithers","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.patol.2026.100859_bib0725","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.5858\/132.12.1929","article-title":"Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue","volume":"132","author":"Hewitt","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.patol.2026.100859_bib0730","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.5858\/arpa.2013-0691-RA","article-title":"A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: how well do you know your FFPE specimen?","volume":"138","author":"Bass","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.patol.2026.100859_bib0735","doi-asserted-by":"crossref","first-page":"983102","DOI":"10.3389\/fmolb.2022.983102","article-title":"Tissue management in precision medicine: what the pathologist needs to know in the molecular era","volume":"9","author":"Souza da Silva","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.patol.2026.100859_bib0740","doi-asserted-by":"crossref","first-page":"103567","DOI":"10.1016\/j.critrevonc.2021.103567","article-title":"The challenge of the molecular tumor board empowerment in clinical oncology practice: a position paper on behalf of the AIOM- SIAPEC\/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies","volume":"169","author":"Russo","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.patol.2026.100859_bib0745","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/jclinpath-2014-202404","article-title":"Guidance for laboratories performing molecular pathology for cancer patients","volume":"67","author":"Cree","year":"2014","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.patol.2026.100859_bib0750","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/his.13891","article-title":"Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study","volume":"75","author":"Dufraing","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.patol.2026.100859_bib0755","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/his.15078","article-title":"Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists","volume":"84","author":"Kerr","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.patol.2026.100859_bib0760","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.3390\/cells9122549","article-title":"BRAF: a two-faced janus","volume":"9","author":"Pisapia","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.patol.2026.100859_bib0765","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/CCO.0000000000001012","article-title":"Pathology and new insights in thyroid neoplasms in the 2022 WHO classification","volume":"36","author":"Lebrun","year":"2024","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.patol.2026.100859_bib0770","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s12105-020-01166-8","article-title":"Comparison of molecular methods and braf immunohistochemistry (VE1 clone) for the detection of BRAF V600E mutation in papillary thyroid carcinoma: a meta-analysis","volume":"14","author":"Parker","year":"2020","journal-title":"Head Neck Pathol"},{"key":"10.1016\/j.patol.2026.100859_bib0775","doi-asserted-by":"crossref","first-page":"102380","DOI":"10.1016\/j.ctrv.2022.102380","article-title":"Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era","volume":"106","author":"Capdevila","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.patol.2026.100859_bib0780","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.patol.2026.100859_bib0785","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.annonc.2020.11.021","article-title":"ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research","volume":"32","author":"Belli","year":"2021","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.patol.2026.100859_bib0790","doi-asserted-by":"crossref","first-page":"351","DOI":"10.5858\/arpa.2020-0376-OA","article-title":"Analytical accuracy of RET fusion detection by break-apart fluorescence in situ hybridization","volume":"146","author":"Baker","year":"2022","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.patol.2026.100859_bib0795","first-page":"100653","article-title":"RET fusion testing in patients with NSCLC: the RETING study","volume":"5","author":"Conde","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.patol.2026.100859_bib0800","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae048","article-title":"Next-generation sequencing in sporadic medullary thyroid cancer patients: mutation profile and disease aggressiveness","volume":"8","author":"Shirali","year":"2024","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.patol.2026.100859_bib0805","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/annonc\/mdz204","article-title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","volume":"30","author":"Marchi\u00f2","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.patol.2026.100859_bib0810","doi-asserted-by":"crossref","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","article-title":"Thyroid carcinoma, version 2.2022. NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Haddad","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.patol.2026.100859_bib0815","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.5858\/arpa.2020-0400-RA","article-title":"Pan-TRK immunohistochemistry: an example-based practical approach to efficiently identify patients with NTRK fusion cancer","volume":"145","author":"Conde","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.patol.2026.100859_bib0820","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5858\/arpa.2022-0443-OA","article-title":"Efficient identification of patients with NTRK fusions using a supervised tumor-agnostic approach","volume":"148","author":"Hernandez","year":"2024","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.patol.2026.100859_bib0825","article-title":"Multicenter harmonization study of Pan-Trk immunohistochemistry for the detection of NTRK3 fusions","volume":"36","author":"Adam","year":"2023","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"10.1016\/j.patol.2026.100859_bib0830","article-title":"Pan-TRK immunohistochemistry to optimize the detection of NTRK fusions: removing the hay when looking for the needle","volume":"36","author":"Conde","year":"2023","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"10.1016\/j.patol.2026.100859_bib0835","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.patol.2026.100859_bib0840","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1038\/sj.onc.1207810","article-title":"Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors","volume":"23","author":"Carlomagno","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.patol.2026.100859_bib0845","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2159-8290.CD-19-1116","article-title":"Advances in targeting RET-dependent cancers","volume":"10","author":"Subbiah","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.patol.2026.100859_bib0850","first-page":"541","article-title":"RET solvent front mutations mediate acquired\u00a0resistance to selective RET inhibition in\u00a0RET-driven malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.patol.2026.100859_bib0855","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.annonc.2020.09.015","article-title":"Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer","volume":"31","author":"Lin","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.patol.2026.100859_bib0860","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1158\/1535-7163.MCT-16-0909","article-title":"Mechanisms of resistance to NTRK inhibitors and therapeutic strategies in NTRK1-rearranged cancers","volume":"16","author":"Fuse","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.patol.2026.100859_bib0865","doi-asserted-by":"crossref","unstructured":"Harada G, Choudhury NJ, Schram AM. Mechanism of acquired resistance to TRK inhibitors. J Clin Oncol. 40 (suppl 16).","DOI":"10.1200\/JCO.2022.40.16_suppl.3104"},{"key":"10.1016\/j.patol.2026.100859_bib0870","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41416-024-02760-1","article-title":"Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents","volume":"131","author":"Roa","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.patol.2026.100859_bib0875","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1210\/jc.2017-02533","article-title":"Pioglitazone therapy of PAX8-PPAR\u03b3 fusion protein thyroid carcinoma","volume":"103","author":"Giordano","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.patol.2026.100859_bib0880","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.3390\/cancers13143443","article-title":"Translational utility of liquid biopsies in thyroid cancer management","volume":"13","author":"Wijewardene","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.patol.2026.100859_bib0885","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1089\/thy.2020.0296","article-title":"Clinical utility of circulating cell-free DNA mutations in anaplastic thyroid carcinoma","volume":"31","author":"Qin","year":"2021","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.patol.2026.100859_bib0890","unstructured":"Konda B, Shah MH, Wei L. Evaluation of BRAF V600E levels in cell free DNA (CFDNA) as a biomarkers of response in BRAF V600E mutated radioactive iodine refractory (RAIR) differentiated thyroid cancer (DTC) treated with dabrafenib alone or in combination with trametinib. Thyroid. 27 (suppl 1):A171\u20132."},{"key":"10.1016\/j.patol.2026.100859_bib0895","unstructured":"Busaidy NL, Cabanillas ME, Sherman SI. Emergence of V804M resistance gatekeeper mutation in sporadic medullary thyroid carcinoma patients treated with TKI tyrosine kinase inhibitors. Thyroid Off J Am Thyroid Assoc. 27 (suppl 1) (A 168)."},{"key":"10.1016\/j.patol.2026.100859_bib0900","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0002","article-title":"Liquid biopsies in thyroid cancers: a systematic review and meta-analysis","volume":"30","author":"Zeyghami","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.patol.2026.100859_bib0905","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S1470-2045(16)30166-8","article-title":"Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial","volume":"17","author":"Brose","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.patol.2026.100859_bib0910","first-page":"1184","article-title":"Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial","volume":"32","author":"Busaidy","year":"2022","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.patol.2026.100859_bib0915","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patol.2026.100859_bib0920","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patol.2026.100859_bib0925","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.patol.2026.100859_bib0930","doi-asserted-by":"crossref","first-page":"S1147","DOI":"10.1016\/j.annonc.2023.09.1085","article-title":"2229P Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: data from LIBRETTO-001","volume":"34","author":"Wirth","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.patol.2026.100859_bib0935","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-21-1259","article-title":"Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma","volume":"186","author":"Waguespack","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.patol.2026.100859_bib0940","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.patol.2026.100859_bib0945","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1200\/JCO.2013.49.6596","article-title":"Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma","volume":"33","author":"Godbert","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.patol.2026.100859_bib0950","doi-asserted-by":"crossref","first-page":"495","DOI":"10.5306\/wjco.v11.i7.495","article-title":"Complete response in anaplastic lymphoma kinase-rearranged oncocytic thyroid cancer: a case report and review of literature","volume":"11","author":"de Salins","year":"2020","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.patol.2026.100859_bib0955","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1009076","article-title":"Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: a case report","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.patol.2026.100859_bib0960","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1530\/ERC-20-0436","article-title":"Targeting EML4-ALK gene fusion variant 3 in thyroid cancer","volume":"28","author":"Aydemirli","year":"2021","journal-title":"Endocr Relat Cancer"}],"container-title":["Revista Espa\u00f1ola de Patolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699885526000048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699885526000048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:32:23Z","timestamp":1776871943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699885526000048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":96,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1699885526000048"],"URL":"https:\/\/doi.org\/10.1016\/j.patol.2026.100859","relation":{},"ISSN":["1699-8855"],"issn-type":[{"value":"1699-8855","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SEAP-GETNE consensus on prognostic and predictive molecular biomarkers in thyroid cancer","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Patolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.patol.2026.100859","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Anatom\u00eda Patol\u00f3gica.","name":"copyright","label":"Copyright"}],"article-number":"100859"}}